LumiraDx Limited (NASDAQ:LMDX – Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 2,950,000 shares, a growth of 2,649.3% from the October 15th total of 107,300 shares. Based on an average daily trading volume, of 8,930,000 shares, the short-interest ratio is presently 0.3 days. Approximately 2.8% of the company’s stock are sold short.
LumiraDx Stock Performance
Shares of LMDX stock opened at $0.09 on Friday. LumiraDx has a 12 month low of $0.08 and a 12 month high of $1.61. The stock has a market cap of $28.99 million, a P/E ratio of -0.08 and a beta of 1.27. The company has a 50 day simple moving average of $0.20 and a two-hundred day simple moving average of $0.36.
LumiraDx (NASDAQ:LMDX – Get Free Report) last announced its earnings results on Thursday, August 24th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). The business had revenue of $21.00 million for the quarter, compared to analyst estimates of $21.07 million. During the same period in the prior year, the company posted ($0.58) earnings per share.
Wall Street Analyst Weigh In
Institutional Trading of LumiraDx
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Colony Group LLC bought a new position in shares of LumiraDx in the second quarter worth approximately $787,000. Renaissance Technologies LLC bought a new position in shares of LumiraDx during the third quarter worth $50,000. Citadel Advisors LLC bought a new position in shares of LumiraDx during the third quarter worth $39,000. Pathstone Family Office LLC bought a new position in shares of LumiraDx during the third quarter worth $47,000. Finally, Balyasny Asset Management LLC boosted its position in shares of LumiraDx by 36,072.9% during the third quarter. Balyasny Asset Management LLC now owns 3,771,385 shares of the company’s stock worth $3,847,000 after acquiring an additional 3,760,959 shares during the last quarter. 9.59% of the stock is owned by hedge funds and other institutional investors.
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
- Five stocks we like better than LumiraDx
- Investing in large cap stocks: Diving into big caps
- MarketBeat Week in Review – 11/6 – 11/10
- Best Stocks Under $10.00
- Data giants MongoDB and Snowflake just got upgraded
- Why Are Stock Sectors Important to Successful Investing?
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for LumiraDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LumiraDx and related companies with MarketBeat.com's FREE daily email newsletter.